Wellstat Therapeutics Corporation (rights to uridine triacetate) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Wellstat Therapeutics Corporation (rights to uridine triacetate) General Information
Description
Distribution rights in the United States of uridine triacetate drug. The drug is used for treating patients at risk of serious toxicity following an overdose of 5-flourouracil.
Contact Information
Corporate Office
- 930 Clopper Road
- Gaithersburg, MD 20878
- United States
Corporate Office
- 930 Clopper Road
- Gaithersburg, MD 20878
- United States
Wellstat Therapeutics Corporation (rights to uridine triacetate) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Wellstat Therapeutics Corporation (rights to uridine triacetate) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Wellstat Therapeutics Corporation (rights to uridine triacetate) FAQs
-
Where is Wellstat Therapeutics Corporation (rights to uridine triacetate) headquartered?
Wellstat Therapeutics Corporation (rights to uridine triacetate) is headquartered in Gaithersburg, MD.
-
What industry is Wellstat Therapeutics Corporation (rights to uridine triacetate) in?
Wellstat Therapeutics Corporation (rights to uridine triacetate)’s primary industry is Buildings and Property.
-
Is Wellstat Therapeutics Corporation (rights to uridine triacetate) a private or public company?
Wellstat Therapeutics Corporation (rights to uridine triacetate) is a Private company.
-
What is Wellstat Therapeutics Corporation (rights to uridine triacetate)’s current revenue?
The current revenue for Wellstat Therapeutics Corporation (rights to uridine triacetate) is
. -
Who are Wellstat Therapeutics Corporation (rights to uridine triacetate)’s investors?
Wellstat Therapeutics Corporation has invested in Wellstat Therapeutics Corporation (rights to uridine triacetate).
-
When was Wellstat Therapeutics Corporation (rights to uridine triacetate) acquired?
Wellstat Therapeutics Corporation (rights to uridine triacetate) was acquired on 06-Jul-2011.
-
Who acquired Wellstat Therapeutics Corporation (rights to uridine triacetate)?
Wellstat Therapeutics Corporation (rights to uridine triacetate) was acquired by BTG.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »